PL3980413T3 - Heterocykliczne immunomodulatory jako inhibitor punktu kontrolnego pdl1 - Google Patents
Heterocykliczne immunomodulatory jako inhibitor punktu kontrolnego pdl1Info
- Publication number
- PL3980413T3 PL3980413T3 PL20730279.5T PL20730279T PL3980413T3 PL 3980413 T3 PL3980413 T3 PL 3980413T3 PL 20730279 T PL20730279 T PL 20730279T PL 3980413 T3 PL3980413 T3 PL 3980413T3
- Authority
- PL
- Poland
- Prior art keywords
- immunomodulators
- heterocyclic
- checkpoint inhibitor
- pdl1
- pdl1 checkpoint
- Prior art date
Links
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 title 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
- 239000002955 immunomodulating agent Substances 0.000 title 1
- 229940121354 immunomodulator Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19179072 | 2019-06-07 | ||
| PCT/EP2020/065646 WO2020245372A1 (en) | 2019-06-07 | 2020-06-05 | Heterocyclic immunomodulators as pdl1 checkpoint inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3980413T3 true PL3980413T3 (pl) | 2023-12-27 |
Family
ID=66793871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20730279.5T PL3980413T3 (pl) | 2019-06-07 | 2020-06-05 | Heterocykliczne immunomodulatory jako inhibitor punktu kontrolnego pdl1 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220259186A1 (pl) |
| EP (1) | EP3980413B1 (pl) |
| JP (1) | JP2022535879A (pl) |
| KR (1) | KR20220017942A (pl) |
| CN (1) | CN113966329A (pl) |
| AU (1) | AU2020286962A1 (pl) |
| BR (1) | BR112021023780A2 (pl) |
| CA (1) | CA3138494A1 (pl) |
| ES (1) | ES2956866T3 (pl) |
| HR (1) | HRP20230873T1 (pl) |
| HU (1) | HUE063236T2 (pl) |
| MA (1) | MA56098B1 (pl) |
| MD (1) | MD3980413T2 (pl) |
| MX (1) | MX2021015048A (pl) |
| PL (1) | PL3980413T3 (pl) |
| RS (1) | RS64681B1 (pl) |
| WO (1) | WO2020245372A1 (pl) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014315457B2 (en) * | 2013-09-04 | 2018-05-10 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| US9850225B2 (en) * | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| US11046675B2 (en) * | 2017-03-27 | 2021-06-29 | Bristol-Myers Squibb Company | Substituted isoquionline derivatives as immunomudulators |
-
2020
- 2020-06-05 CA CA3138494A patent/CA3138494A1/en active Pending
- 2020-06-05 KR KR1020217042602A patent/KR20220017942A/ko unknown
- 2020-06-05 HU HUE20730279A patent/HUE063236T2/hu unknown
- 2020-06-05 JP JP2021572339A patent/JP2022535879A/ja active Pending
- 2020-06-05 MA MA56098A patent/MA56098B1/fr unknown
- 2020-06-05 CN CN202080041699.XA patent/CN113966329A/zh active Pending
- 2020-06-05 EP EP20730279.5A patent/EP3980413B1/en active Active
- 2020-06-05 RS RS20230805A patent/RS64681B1/sr unknown
- 2020-06-05 MD MDE20220403T patent/MD3980413T2/ro unknown
- 2020-06-05 HR HRP20230873TT patent/HRP20230873T1/hr unknown
- 2020-06-05 MX MX2021015048A patent/MX2021015048A/es unknown
- 2020-06-05 WO PCT/EP2020/065646 patent/WO2020245372A1/en active Application Filing
- 2020-06-05 AU AU2020286962A patent/AU2020286962A1/en active Pending
- 2020-06-05 BR BR112021023780A patent/BR112021023780A2/pt unknown
- 2020-06-05 PL PL20730279.5T patent/PL3980413T3/pl unknown
- 2020-06-05 US US17/595,711 patent/US20220259186A1/en active Pending
- 2020-06-05 ES ES20730279T patent/ES2956866T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020245372A1 (en) | 2020-12-10 |
| RS64681B1 (sr) | 2023-11-30 |
| HRP20230873T1 (hr) | 2024-02-16 |
| ES2956866T3 (es) | 2023-12-29 |
| BR112021023780A2 (pt) | 2022-01-11 |
| CA3138494A1 (en) | 2020-12-10 |
| MA56098A (fr) | 2022-04-13 |
| MX2021015048A (es) | 2022-01-18 |
| EP3980413B1 (en) | 2023-07-19 |
| US20220259186A1 (en) | 2022-08-18 |
| KR20220017942A (ko) | 2022-02-14 |
| AU2020286962A1 (en) | 2022-02-03 |
| JP2022535879A (ja) | 2022-08-10 |
| HUE063236T2 (hu) | 2024-01-28 |
| EP3980413A1 (en) | 2022-04-13 |
| EP3980413C0 (en) | 2023-07-19 |
| MA56098B1 (fr) | 2023-10-31 |
| CN113966329A (zh) | 2022-01-21 |
| MD3980413T2 (ro) | 2023-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277539A (en) | The heterocyclic compounds as immunomodulators | |
| HK1249905A1 (zh) | 作為lsd1抑制劑的雜環化合物 | |
| IL276509A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL273428A (en) | Heterocyclic compounds as PAD inhibitors | |
| SG10202110874TA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| IL290508A (en) | Heterocyclic compounds as kinase inhibitors | |
| GB201705971D0 (en) | Inhibitor compounds | |
| IL289439A (en) | Heterocyclic compounds as bet inhibitors | |
| IL282659A (en) | Heterocyclic compounds as bet inhibitors | |
| IL289617A (en) | Heterocyclic compounds | |
| IL289595A (en) | Heterocyclic compounds | |
| GB201819126D0 (en) | Inhibitor compounds | |
| IL290087A (en) | inhibitory substances | |
| IL288987A (en) | New heterocyclic compounds | |
| GB201914860D0 (en) | Inhibitor compounds | |
| IL289389A (en) | Heterocyclic compounds as kinase inhibitors | |
| EP3980413C0 (en) | HETEROCYCLIC IMMUNOMODULATORS AS PDL1 CHECKPOINT INHIBITORS | |
| GB201905328D0 (en) | Inhibitor compounds | |
| GB201905318D0 (en) | Inhibitor compounds | |
| HK1252918A1 (zh) | 作為erk抑制劑的雜環化合物 | |
| GB201819136D0 (en) | Inhibitor compounds | |
| GB201806130D0 (en) | Inhibitor compounds | |
| GB201806131D0 (en) | Inhibitor compounds | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors |